Navigation Links
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
Date:5/15/2009

comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including an ongoing accelerated approval study in heavily pre-treated relapsed/refractory patients and a Phase 2 trial in relapsed patients. A Phase Ib clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the latest information regarding ongoing carfilzomib clinical trials, please visit www.clinicaltrials.gov.

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Proteolix is also developing a pipeline of novel proteasome inhibitors, including a selective, oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit www.proteolix.com.


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
4. Proteolix Raises $79 Million in Series C Financing
5. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
8. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
9. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
10. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
11. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)... 18, 2014   Sterne, Kessler, Goldstein & Fox ... Washington, DC , announced today that it ... (IPR) with the U.S. Patent and Trademark Office ... BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions aim ... Myriad Genetics, Inc. These patents have been asserted against ...
(Date:8/18/2014)... According to a new ... Science Reagents Market(Products- PCR Reagent Kits, Cell and ... Reagents and Others; End Users- Commercial and Contract ... Forensic Laboratories)- Global Industry Analysis, Size, Share, Growth, ... life science reagents market was valued at USD ...
(Date:8/18/2014)... 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... on Form 10 with the U.S. Securities and ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form ...
Breaking Biology Technology:Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4
... ... in Chicago. , ... Chicago (Vocus) April 22, 2010 -- Therapeutic Proteins Inc. (TPI) today announced ... constructed to meet U.S. Food and Drug Administration (FDA) requirements. The Chicago facility is ...
... a tactile-based probe technique, provides a three-dimensional nanoscale image ... the material,s surface. The core of AFM imaging workhorse ... as it encounters undulations across a surface. Due ... cantilevers can deform or even tear apart living ...
... ... Shear Processing Leader Applies For Microfluidics Reaction Technology™ (MRT) Patent in Japan ... Newton, ... that, along with its exclusive Japanese distributor, POWREX Corporation, it has introduced Microfluidics ...
Cached Biology Technology:Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 2Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 3Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 4A little less force: Making atomic force microscopy work for cells 2Microfluidics and POWREX Launch Revolutionary Continuous Pharmaceutical Manufacturing Technology in Japan 2Microfluidics and POWREX Launch Revolutionary Continuous Pharmaceutical Manufacturing Technology in Japan 3
(Date:8/19/2014)... study that analyzed concentrations of African dust transported ... winter and spring. These research findings offer new ... quality impacts of African dust, including the climate ... occur from increased African dust emissions in the ... (UM) Rosenstiel School of Marine and Atmospheric Science ...
(Date:8/19/2014)... available in French . ... and RISKS of physical activity in children,Today the Canadian ... promotion of childhood physical activity and published their position ... and Metabolism ( APNM ). This position ... area of risk of physical activity for children and ...
(Date:8/19/2014)... Florida , August 19, 2014 ... Options / Digital Wallet Choices as latest developments, ad ... eBay Inc. (NASDAQ: EBAY ), Amazon.com Inc. ... AAPL ), Google Inc. (NASDAQ: GOOG ... Inc., (OTCQB: NXTD) a biometric authentication company focused on ...
Breaking Biology News(10 mins):Study of African dust transport to South America reveals air quality impacts 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7
... Pennsylvania studying oocytes in mice, the immature egg cells ... in microRNA, or miRNA, activity that may be the ... blastomeres of the embryo. MicroRNAs are a member of ... of the biological world. MicroRNAs imperfectly pair with ...
... , HASBROUCK HEIGHTS, N.J. , Feb. 3 Zymes ... Omega-3 enhanced water, will be sampled at the NFL Alumni,s Super Bowl ... Florida .  This presence of OmegaChill at Super Bowl XLIV ... term heart and mind health will serve as keynotes to Zymes LLC,s ...
... investigate whether long-term weekly iron and folic acid supplementation ... malaria. The information provided by the study, based in ... health services and develop effective preventative programmes for anaemia ... during or shortly after adolescence may enter pregnancy with ...
Cached Biology News:Penn biologists determine microRNA activity is suppressed in mouse ovum 2Zymes LLC's Omega-3 Enhanced Water OmegaChill to be Distributed at NFL Alumni Super Bowl XLIV Weekend Events on February 5-7th, 2010 2LSTM begins £0.5 million malaria study in Burkina Faso 2
... The Genome Sequencer 20 System revolutionizes DNA ... parallel fashion. The Genome Sequencer 20 ... Reagents and consumables for library construction, ... mapping and de novo assembly ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
... demonstrated that oxidative stress is involved in ... stress is the condition in which an ... exist leading to the damage of a ... stress is through several antioxidant systems4 that ...
Biology Products: